ataticept

News

Vertex chief executive Reshma Kewalramani

Vertex preps FDA filing for IgAN drug after phase 3 readout

Vertex's bid to expand beyond cystic fibrosis has taken a big step forward with phase 3 data for povetacicept in severe kidney disorder IgAN.

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

News

Otsuka, Vera stake their claims to IgAN treatment

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?

Vertex preps FDA filing for IgAN drug after phase 3 readout

Otsuka joins IgAN market with Voyxact approval in US

Otsuka, Vera stake their claims to IgAN treatment

Acquisitive Lilly offers $2.88bn for Merida Bio

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks